Multimodality Therapy for Pancreatic Cancer

Gastroenterology Clinics of North America

Volumn 36, Issue 2, 2007, Pages 391-411

  Franko, Jan ^a   Greer, Julia B ^a   Moran, Coleen M ^a   Khalid, Asif ^a   Moser, A James ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DIPYRIDAMOLE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; MITOMYCIN C; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; TANOMASTAT; TIPIFARNIB; TRASTUZUMAB;

ADVANCED CANCER; BILE DUCT TUMOR; BILIARY TRACT DISEASE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CHOLANGITIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DEHYDRATION; DRUG FATALITY; DRUG TARGETING; DUODENUM CANCER; EVIDENCE BASED MEDICINE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; MELANOMA; META ANALYSIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NAUSEA; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PATIENT SAFETY; PATIENT SELECTION; PEROPERATIVE CARE; PROGNOSIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VATER PAPILLA TUMOR; VOMITING; WEIGHT REDUCTION;

COMBINED MODALITY THERAPY; HUMANS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 34249079410     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2007.03.004     Document Type: Review

References (113)

1. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 60 (1987) 2284-2303
2. Lowenfels A.B., and Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 20 (2006) 197-209
3. Sener S.F., Fremgen A., Menck H.R., et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. [see comment]. J Am Coll Surg 189 (1999) 1-7
4. Ghaneh P., Sultana A., Shore S., et al. The case for adjuvant chemotherapy in pancreatic cancer. Best Pract Res Clin Gastroenterol 20 (2006) 383-401
5. Bramhall S.R., Allum W.H., Jones A.G., et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. [see comment]. Br J Surg 82 (1995) 111-115
6. Sperti C., Pasquali C., Piccoli A., et al. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 21 (1997) 195-200
7. Shaib Y.H., Davila J.A., and El-Serag H.B. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther 24 (2006) 87-94
8. Niederhuber J.E., Brennan M.F., and Menck H.R. The National Cancer Data Base report on pancreatic cancer. Cancer 76 (1995) 1671-1677
9. Keedy V.L., and Berlin J. Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer. Curr Treat Options Oncol 7 (2006) 381-388
10. Pilepich M.V., and Miller H.H. Preoperative irradiation in carcinoma of the pancreas. Cancer 46 (1980) 1945-1949
11. Kopelson G. Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: the role of adjuvant pre or postoperative radiation therapy. Int J Radiat Oncol Biol Phys 9 (1983) 911-915
12. Ishikawa O., Ohhigashi H., Teshima T., et al. Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region. J Surg Oncol 40 (1989) 143-151
13. Weese J.L., Nussbaum M.L., Paul A.R., et al. Increased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemoradiotherapy. Int J Pancreatol 7 (1990) 177-185
14. White R.R., Xie H.B., Gottfried M.R., et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. [see comment]. Ann Surg Oncol 12 (2005) 214-221
15. Staley C.A., Lee J.E., Cleary K.R., et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 171 (1996) 118-124
16. Talamonti M.S., Small Jr. W., Mulcahy M.F., et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. [see comment]. Ann Surg Oncol 13 (2006) 150-158
17. Sohn T.A., and Lillemoe K.D. Surgical palliation of pancreatic cancer. Advances in Surgery 34 (2000) 249-271
18. Nemoto K., Ogawa Y., Sakayauchi T., et al. Radiation therapy for locally advanced pancreatic cancer. [Japanese]. Nippon Rinsho 1 (2006) 190-193
19. Brown M.W., Ning H., Arora B., et al. A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 65 (2006) 274-283
20. Marsh R.W., and George T. Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma. Curr Gastroenterol Rep 8 (2006) 111-120
21. Cameron J.L., Riall T.S., Coleman J., et al. One thousand consecutive pancreaticoduodenectomies. [see comment]. Ann Surg 244 (2006) 10-15
22. Koong A.C., Le Q.T., Ho A., et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1017-1021
23. Fenwick J.D., Tome W.A., Soisson E.T., et al. Tomotherapy and other innovative IMRT delivery systems. Semin Radiat Oncol 16 (2006) 199-208
24. Pishvaian A.C., Collins B., Gagnon G., et al. EUS-guided fiducial placement for CyberKnife radiotherapy of mediastinal and abdominal malignancies. [see comment]. Gastrointest Endosc 64 (2006) 412-417
25. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. [see comment]. JAMA 297 (2007) 267-277
26. Park J.K., Ryu J.K., Lee J.K., et al. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. Pancreas 33 (2006) 397-402
27. de Castro S.M., Kuhlmann K.F., van Heek N.T., et al. Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. J Gastrointest Surg 8 (2004) 775-784
28. Chatelain D., and Flejou J.F. Pancreatectomy for adenocarcinoma: prognostic factors, recommendations for pathological reports. [French]. Ann Pathol 22 (2002) 422-431
29. Nakao A. Debate: extended resection for pancreatic cancer; the affirmative case. J Hepatobiliary Pancreat Surg 10 (2003) 57-60
30. Penberthy D.R., Rich T.A., and Adams R.B. Postoperative adjuvant therapy for pancreatic cancer. Semin Surg Oncol 21 (2003) 256-260
31. Nakao A., Takeda S., Sakai M., et al. Extended radical resection versus standard resection for pancreatic cancer: the rationale for extended radical resection. Pancreas 28 (2004) 289-292
32. Sohn T.A., Yeo C.J., Cameron J.L., et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. [see comment]. J Gastrointest Surg 4 (2000) 567-579
33. Leach S.D., Lee J.E., Charnsangavej C., et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 85 (1998) 611-617
34. Tseng J.F., Raut C.P., Lee J.E., et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 8 (2004) 935-949
35. Launois B., Stasik C., Bardaxoglou E., et al. Who benefits from portal vein resection during pancreaticoduodenectomy for pancreatic cancer?. World J Surg 23 (1999) 926-929
36. Nakagohri T., Kinoshita T., Konishi M., et al. Survival benefits of portal vein resection for pancreatic cancer. Am J Surg 186 (2003) 149-153
37. Fortner J.G. Regional resection of cancer of the pancreas: a new surgical approach. Surgery 73 (1973) 307-320
38. Fortner J.G. Regional resection and pancreatic carcinoma. Surgery 73 (1973) 799-800
39. Fortner J.G., Klimstra D.S., Senie R.T., et al. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 223 (1996) 147-153
40. Pedrazzoli S., DiCarlo V., Dionigi R., et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 228 (1998) 508-517
41. Schwarz R.E., and Smith D.D. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol 13 (2006) 1189-1200
42. Yeo C.J., Cameron J.L., Lillemoe K.D., et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 236 (2002) 355-366
43. Westerdahl J., Andren-Sandberg A., and Ihse I. Recurrence of exocrine pancreatic cancer: local or hepatic?. Hepatogastroenterology 40 (1993) 384-387
44. Inoue K., Hiraoka T., Kanemitsu K., et al. Onset of liver metastasis after histologically curative resection of pancreatic cancer. Surg Today 36 (2006) 252-256
45. White R.R., Paulson E.K., Freed K.S., et al. Staging of pancreatic cancer before and after neoadjuvant chemoradiation. J Gastrointest Surg 5 (2001) 626-633
46. Sa Cunha A., Rault A., Laurent C., et al. Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg 201 (2005) 359-365
47. Pendurthi T.K., Hoffman J.P., Ross E., et al. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. Am Surg 64 (1998) 686-692
48. Evans D.B., Rich T.A., Byrd D.R., et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127 (1992) 1335-1339
49. Evans D.B. Preoperative chemoradiation for pancreatic cancer. Semin Oncol 32 6 Suppl 9 (2005) S25-S29
50. Ch'ang H.J., Wang C.C., Cheng A.L., et al. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. J Gastroenterol Hepatol 21 (2006) 874-879
51. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (2004) 1200-1210
52. Benzoni E., Terrosu G., Bresadola V., et al. Analysis of clinical outcomes and prognostic factors of neoadjuvant chemoradiotherapy combined with surgery: intraperitoneal versus extraperitoneal rectal cancer. Eur J Cancer Care (Engl) 15 (2006) 286-292
53. Chadwick M.A., Vieten D., Pettitt E., et al. Short course preoperative radiotherapy is the single most important risk factor for perineal wound complications after abdominoperineal excision of the rectum. Colorectal Dis 8 (2006) 756-761
54. Bilchik A.J., Poston G., Curley S.A., et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. [see comment]. [erratum appears in J Clin Oncol. 2006 Apr 1;24(10):1648]. J Clin Oncol 23 (2005) 9073-9078
55. Hermann R.M., Horstmann O., Haller F., et al. Histomorphological tumor regression grading of esophageal carcinoma after neoadjuvant radiochemotherapy: which score to use?. Dis Esophagus 19 (2006) 329-334
56. Hofler H., Langer R., Ott K., et al. Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. Adv Exp Med Biol 587 (2006) 115-120
57. Krdal V., Neoral C., Aujesky R., et al. Neoadjuvant therapy for esophageal cancer: what can we accept?. Hepatogastroenterology 53 (2006) 720-722
58. MacGuill M., Mulligan E., Ravi N., et al. Clinicopathologic factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer. Dis Esophagus 19 (2006) 273-276
59. Piraino A., Vita M.L., Tessitore A., et al. Neoadjuvant therapy for esophageal cancer: surgical considerations. Rays 31 (2006) 37-45
60. Heller W., Mazhar D., Ward R., et al. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer. Oncol Rep 17 (2007) 253-259
61. Pickles M.D., Gibbs P., Lowry M., et al. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 24 (2006) 843-847
62. Tubiana-Hulin M., Stevens D., Lasry S., et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 17 (2006) 1228-1233
63. Le Pechoux C., Pautier P., Delannes M., et al. Clinical practice guidelines: 2006 update of recommendations for the radiotherapeutic management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and retroperitoneal sarcoma. [French]. Cancer Radiother 10 (2006) 185-207
64. Pappo A.S., Devidas M., Jenkins J., et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. [see comment]. J Clin Oncol 23 (2005) 4031-4038
65. Scurr M., and Judson I. Neoadjuvant and adjuvant therapy for extremity soft tissue sarcomas. Hematol Oncol Clin North Am 19 (2005) 489-500
66. Scoggins C.R., and Pollock R.E. Extremity soft tissue sarcoma: evidence-based multidisciplinary management. J Surg Oncol 90 (2005) 10-13
67. White R.R., Hurwitz H.I., Morse M.A., et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. [see comment]. Ann Surg Oncol 8 (2001) 758-765
68. Kouloulias V.E., Nikita K.S., Kouvaris J.R., et al. Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma. Eur J Cancer Care (Engl) 11 (2002) 100-107
69. Mehta V.K., Fisher G., Ford J.A., et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg 5 (2001) 27-35
70. Hoffman J.P., Lipsitz S., Pisansky T., et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 16 (1998) 317-323
71. Mishra G., Butler J., Ho C., et al. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol 28 (2005) 345-350
72. Mornex F., Girard N., Scoazec J.Y., et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: the French SFRO-FFCD 97-04 Phase II trial. Int J Radiat Oncol Biol Phys 65 (2006) 1471-1478
73. Moutardier V., Magnin V., Turrini O., et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 60 (2004) 437-443
74. Moutardier V., Turrini O., Huiart L., et al. A reappraisal of preoperative chemoradiation for localized pancreatic head ductal adenocarcinoma in a 5-year single-institution experience. J Gastrointest Surg 8 (2004) 502-510
75. Turrini O., Moutardier V., Guiramand J., et al. Hemorrhage after duodenopancreatectomy: impact of neoadjuvant radiochemotherapy and experience with sentinel bleeding. World J Surg 29 (2005) 212-216
76. Ammori J.B., Colletti L.M., Zalupski M.M., et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 7 (2003) 766-772
77. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. [see comment]. J Clin Oncol 15 (1997) 2403-2413
78. Moertel C.G., Childs Jr. D.S., Reitemeier R.J., et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2 (1969) 865-867
79. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. [see comment]. Ann Surg 230 (1999) 776-782
80. Neoptolemos J.P., Dunn J.A., Stocken D.D., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. [see comment]. Lancet 358 (2001) 1576-1585
81. Stocken D.D., Buchler M.W., Dervenis C., et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 92 (2005) 1372-1381
82. Regine W.F., Winter K.W., Abrams R., et al. RTOG 9704: a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol 24 18S (2006) 4007
83. Safran H., Moore T., Iannitti D., et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 49 (2001) 1275-1279
84. Epelbaum R., Rosenblatt E., Nasrallah S., et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 81 (2002) 138-143
85. Li C.P., Chao Y., Chi K.H., et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. [see comment]. Int J Radiat Oncol Biol Phys 57 (2003) 98-104
86. Magnin V., Moutardier V., Giovannini M.H., et al. Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys 55 (2003) 1300-1304
87. Viret F., Ychou M., Goncalves A., et al. Docetaxel and radiotherapy and pancreatic cancer. Pancreas 27 (2003) 214-219
88. Rich T.M.D., Harris J., Abrams R.M., et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 27 (2004) 51-56
89. Magnin V., Viret F., Moutardier V., et al. Complete pathologic responses to preoperative chemoradiation in two patients with adenocarcinoma of the pancreas. Pancreas 28 (2004) 103-104
90. Kim H.J., Czischke K., Brennan M.F., et al. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?. J Gastrointest Surg 6 (2002) 763-769
91. Todd K.E., Gloor B., Lane J.S., et al. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole. J Gastrointest Surg 2 (1998) 159-166
92. Wanebo H.J., Glicksman A.S., Vezeridis M.P., et al. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg 135 (2000) 81-87
93. Snady H., Bruckner H., Cooperman A., et al. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89 (2000) 314-327
94. Roder J.D., Stein H.J., and Siewert J.R. Carcinoma of the periampullary region: who benefits from portal vein resection?. Am J Surg 171 (1996) 170-175
95. Breslin T.M., Hess K.R., Harbison D.B., et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8 (2001) 123-132
96. Pisters P.W., Wolff R.A., Janjan N.A., et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 20 (2002) 2537-2544
97. Manabe T., Ohshio G., Baba N., et al. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 64 (1989) 1132-1137
98. Nitecki S.S., Sarr M.G., Colby T.V., et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas: is it really improving?. Ann Surg 221 (1995) 59-66
99. Yeo C.J., Cameron J.L., Lillemoe K.D., et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 221 (1995) 721-731
100. Gagandeep S., Artinyan A., Jabbour N., et al. Extended pancreatectomy with resection of the celiac axis: the modified Appleby operation. Am J Surg 192 (2006) 330-335
101. Ohigashi H., Ishikawa O., Eguchi H., et al. Feasibility and efficacy of combination therapy with preoperative and postoperative chemoradiation, extended pancreatectomy, and postoperative liver perfusion chemotherapy for locally advanced cancers of the pancreatic head. Ann Surg Oncol 12 (2005) 629-636
102. Safran H., Iannitti D., Ramanathan R., et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 22 (2004) 706-712
103. Xiong H.Q., Rosenberg A., LoBuglio A., et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 22 (2004) 2610-2616
104. Moore M.J. Brief communication: a new combination in the treatment of advanced pancreatic cancer. Semin Oncol 32 (2005) 5-6
105. Ottaviano A.J., Sun L., Ananthanarayanan V., et al. Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1. Cancer Res 66 (2006) 7032-7040
106. Bloomston M., Bhardwaj A., Ellison E.C., et al. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg 23 (2006) 74-79
107. Durkin A.J., Osborne D.A., Yeatman T.J., et al. EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma. J Surg Res 135 (2006) 195-201
108. Miyake K., Tsuchida K., Sugino H., et al. Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha. Cancer Chemother Pharmacol 59 (2007) 113-126
109. Picozzi V.J., Kozarek R.A., and Traverso L.W. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185 (2003) 476-480
110. Eklund J.W., and Kuzel T.M. Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma. Cancer Treat Res 126 (2005) 263-287
111. Spanknebel K., Cheung K.Y., Stoutenburg J., et al. Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2. [see comment]. Ann Surg Oncol 12 (2005) 381-390
112. Angelini C., Bovo G., Muselli P., et al. Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results. Hepatogastroenterology 53 (2006) 141-144
113. Brennan M.F., Moccia R.D., and Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg 223 (1996) 506-511